GlassScriptPhysician profile
Amanda M Barritt
NPI 1114644770
$2,375.81
in general payments reported to CMS, 2019-2025
31 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $282 · 2023: $692 · 2024: $302 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,093.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $506.88 | 2023-2025 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $309.68 | 2025 | Fasenra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.39 | 2022-2025 | Jardiance, Jascayd, Synjardy |
| Collegium Pharmaceutical, INC. | $155.35 | 2023-2024 | Belbuca, Xtampza |
| Sanofi-Aventis U.S. LLC | $113.05 | 2022-2023 | |
| Novo Nordisk INC | $99.68 | 2022 | |
| Genzyme Corporation | $86.26 | 2025 | |
| Insmed, INC. | $77.59 | 2025 | Brinsupri, Arikayce |
| Lilly USA, LLC | $74.67 | 2022-2023 | Jardiance, Lyumjev |
| Glaxosmithkline, LLC. | $61.14 | 2025 | Trelegy Ellipta, Nucala |
| United Therapeutics Corporation | $60.86 | 2025 | Tyvaso |
| Dexcom, INC. | $60.65 | 2023 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $55.01 | 2025 | Yupelri |
| Insulet Corporation | $49.36 | 2023 | Omnipod |
| Ibsa Pharma INC. | $47.83 | 2022-2023 | Tirosint, Licart |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $46.79 | 2023 | Korlym |
| Verona Pharma, INC. | $46.11 | 2025 | Ohtuvayre |
| Abbvie INC. | $41.20 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.42 | 2022-2023 | |
| Mannkind Corporation | $31.78 | 2023 | Afrezza |
| Regeneron Healthcare Solutions, INC. | $31.35 | 2025 | Dupixent |
| Forte Bio-Pharma LLC | $31.17 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Baxter Healthcare | $25.79 | 2025 | Hillrom - Monarch Airway Clearance System |
| Merck Sharp & Dohme LLC | $20.42 | 2025 | Winrevair |
| Jazz Pharmaceuticals INC. | $19.51 | 2025 | |
| Amryt Pharma Holdings LTD | $17.90 | 2023 | Myalept |
| Philips North America LLC | $14.81 | 2025 | Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $13.52 | 2025 | Opsynvi |
| Xeris Pharmaceuticals, INC. | $13.16 | 2023 | Keveyis |
| 3b Medical, INC. | $12.72 | 2025 | Luna |
| Cequr Corporation | $9.76 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Barritt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.